Therefore, endocrine therapy, mainly through inhibition of AR-signalling activity by antiandrogens (e.g., flutamide, bicalutamide, etc.), has been the mainstay of hormone therapy for prostate cancer over the last few decades [2]. The gene discussed is AR; the disease is Familial prostate cancer.